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The La Crosse Virus (LACV) M segment encodes two glycoproteins (Gn and Gc), and plays a critical role in the neuropathogenesis of LACV
infection as the primary determinant of neuroinvasion. A recent study from our group demonstrated that the region comprising the membrane
proximal two-thirds of Gc, amino acids 860–1442, is critical in mediating LACV fusion and entry. Furthermore, computational analysis identified
structural similarities between a portion of this region, amino acids 970–1350, and the E1 fusion protein of two alphaviruses: Sindbis virus and
Semliki Forrest virus (SFV). Within the region 970–1350, a 22-amino-acid hydrophobic segment (1066–1087) is predicted to correlate structurally
with the fusion peptides of class II fusion proteins. We performed site-directed mutagenesis of key amino acids in this 22-amino acid segment and
determined the functional consequences of these mutations on fusion and entry. Several mutations within this hydrophobic domain affected
glycoprotein expression to some extent, but all mutations either shifted the pH threshold of fusion below that of the wild-type protein, reduced fusion
efficiency, or abrogated cell-to-cell fusion and pseudotype entry altogether. These results, coupled with the aforementioned computational modeling,
suggest that the LACV Gc functions as a class II fusion protein and support a role for the region Gc 1066–1087 as a fusion peptide.
© 2006 Elsevier Inc. All rights reserved.Keywords: Virus fusion; La Crosse Virus; Bunyavirus; Glycoprotein; Fusion peptideIntroduction
The Bunyaviridae are a diverse family of RNA viruses
divided into 5 genera (Orthobunyavirus, Hantavirus, Nairo-
virus, Phlebovirus, and Tospovirus). With the exception of
viruses in the genus Hantavirus, most bunyaviruses are
arthropod borne. Members of the Bunyaviridae cause human
illnesses ranging from mild, asymptomatic infection to
pulmonary disease, hemorrhagic fever, and fatal encephalitis
(reviewed in Soldan and Gonzalez-Scarano, 2005); specifically,
several of the orthobunyaviruses are associated with neurolog-⁎ Corresponding author. Department of Neurology, 3 West Gates, Hospital of
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doi:10.1016/j.virol.2006.08.050ical complications including encephalitis and congenital CNS
abnormalities (Soldan and Gonzalez-Scarano, 2005). Among
these viruses, the best studied and the focus of this report is La
Crosse Virus (LACV), a member of the California serogroup of
orthobunyaviruses. LACV is an important cause of pediatric
encephalitis and aseptic meningitis in the United States, chiefly
in areas where its primary mosquito vector, Ochlerotatus
(formerly, Aedes) triseriatus, resides (Thompson et al., 1965).
The bunyavirus genome contains three single-stranded RNA
segments of negative polarity, designated according to size as
small (S), medium (M), and large (L). These segments are
encapsidated by a nucleocapsid (N) protein to form helical
ribonucleoprotein complexes (RNPs). The L RNA segment
encodes the viral polymerase that is responsible for both
transcription and replication of the genome (Roberts et al.,
1995). The S RNA segment encodes the N protein and, for the
orthobunyaviruses, tospoviruses, and phleboviruses, a non-
Table 1
Alignment of the putative Gc fusion peptides from representative members of
the five genera of the Bunyaviridae (adapted from Garry and Garry, 2004)
1Rift Valley Fever Virus, a phlebovirus;
2
Tomato Spotted Wilt Virus, a
tospovirus; 3La Crosse Virus an orthobunyavirus; 4Hantaan Virus, a hantavirus;
5Crimean-Congo Hemorrhagic Fever Virus, a nairovirus. Conserved cystein
residues in red, LACV amino acid residues subjected to site-directed
mutagenesis in blue and enclosed.
274 M.L. Plassmeyer et al. / Virology 358 (2007) 273–282structural protein (NSs) through an overlapping reading frame
(orthobunyaviruses) or an ambisense coding mechanism
(phleboviruses, tospoviruses). The M RNA segment encodes
a single open reading frame (ORF) that is processed into the
surface transmembrane glycoproteins Gn (formerly called G2)
and Gc (formerly G1) and, for the orthobunyaviruses and some
members of the genus Phlebovirus, a non-structural protein
(NSm) of unknown function. The two surface transmembrane
glycoproteins, Gn and Gc, associate as a heteromultimer after
cleavage of the precursor polyprotein (Bupp et al., 1996; Eshita
and Bishop, 1984; Fazakerley et al., 1988). This Gc/Gn
heteromultimer is targeted to the Golgi apparatus, the site of
viral assembly and budding, by a localization signal encoded
within Gn (Bertolotti-Ciarlet et al., 2005; Bupp et al., 1996;
Chen et al., 1991; Haferkamp et al., 2005; Lappin et al., 1994;
Ruusala et al., 1992). LACV Gc, the larger of the two
glycoproteins, is the exclusive target of neutralizing antibodies
and plays a critical role in entry as it is the virus attachment
protein (Gonzalez-Scarano et al., 1982; Grady et al., 1983;
Pekosz et al., 1995a, 1995b). In addition, both Gc and a soluble
form of Gc lacking a transmembrane domain form homo-
multimers and undergo a pH-dependent conformational
change that is associated with virus-cell or cell-to-cell fusion
(Gonzalez-Scarano, 1985; Gonzalez-Scarano et al., 1984;
Pekosz and Gonzalez-Scarano, 1996).
Previous studies using wild-type LACV and TAH181/57, a
highly neurovirulent brain passaged strain of the closely
related Tahyna virus with low neuroinvasiveness, mapped the
neuroinvasive phenotype to the M segment. (Gonzalez-
Scarano et al., 1982; Janssen et al., 1984). In complementary
experiments, LACV monoclonal antibody escape variants V22
and V22F, generated with a monoclonal antibody against Gc
(807–22), were associated with a more limited viremia and a
decreased ability to mediate cell-to-cell fusion (Gonzalez-
Scarano et al., 1985; Sundin et al., 1987). Further, V22/V22F-
mediated fusion occurred at a lower pH than that routinely
observed for wild-type LACV, suggesting that Gc is the
primary determinant of neuroinvasion and pH-dependent
fusion (Gonzalez-Scarano et al., 1985; Sundin et al., 1987).
More recently, a panel of recombinant M segment constructs
using LACV, TAH818/57, and the V22 variants were used to
further delineate the molecular basis of cell-to-cell fusion and
entry in California serogroup bunyaviruses (Plassmeyer et al.,
2005). This study demonstrated that the region corresponding
roughly to the membrane proximal two-thirds of Gc, amino
acids 860–1442, is critical in mediating fusion and entry
(Plassmeyer et al., 2005). Computational analysis then
identified structural similarities between the LACV Gc
amino acid region 970–1350 and the E1 fusion protein of
two alphaviruses: Sindbis virus and Semliki Forrest virus
(SFV) (Zhang et al., 2002; Plassmeyer et al., 2005).
Collectively, these data suggested that the LACV Gc, like
the alphavirus E1 and flavivirus E, functions as a class II
fusion protein.
Within the 970–1350 region there is a 22-amino-acid
hydrophobic segment (1066–1087) that is predicted to
correlate structurally with a hydrophobic domain of theSindbis virus E1 (Garry and Garry, 2004; Plassmeyer et al.,
2005). Although the LACV Gc and SFV E1 do not share
significant amino acid sequence homology, there is a marked
conservation of individual cysteine residues in these hydro-
phobic regions. The three conserved cysteine residues (Levy-
Mintz and Kielian, 1991) of the SFV E1 fusion domain, two
of which form disulfide bonds with an adjacent loop that helps
maintain the loop structure, are critical for fusion activity
(Lescar et al., 2001). The presence of an internal fusion loop
within a disulfide-stabilized loop has also been demonstrated
for the fusion peptide of Tick-Borne Encephalitis Virus
(TBEV) (E) and of avian sarcoma-leukosis virus (ASLV)
(Rey et al., 1995; Delos et al., 2000; Delos and White, 2000;
Hernandez and White, 1998).
The presence of conserved cysteine residues within the
hydrophobic domain of LACV Gc delineated by amino acids
1066–1087 as well as the relative conservation of this region
among disparate members of the Bunyaviridae (Table 1) (Garry
and Garry, 2004; Plassmeyer et al., 2005), suggest that this
hydrophobic region may form a similar disulfide-stabilized loop
structure and serve as a fusion peptide. To test this hypothesis,
we substituted key amino acids within this putative 22-amino-
acid fusion peptide. The functional effects of these mutations
were then assessed using cell-to-cell fusion and pseudotype
transduction assays (Ma et al., 1999; Plassmeyer et al., 2005).
Several mutations within this hydrophobic domain affected
glycoprotein expression to some extent, but all mutations either
shifted the pH threshold of fusion below that of the wild-type
protein, reduced fusion efficiency, or abrogated cell-to-cell
fusion and pseudotype entry altogether. A mutation at position
1066 (W1066A) was particularly informative, since it did not
affect glycoprotein expression, yet abolished fusion and entry.
Collectively, these results support a role for the region Gc
1066–1087, as the LACV Gc fusion peptide.
Results
Generation of LACV Gc (1066–1087) and (Gc 761) mutant
constructs
We took several approaches to analyzing this putative
fusion domain: we (a) substituted several conserved and non-
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1087), (b) deleted the region in mutant LACV (Δ1066–1087)
and (c) prepared an insertion mutant containing the entire
fusion peptide of SFV, LACV (SFV-FP). The mutagenesis was
accomplished with the QuikChange II XL site-directed
mutagenesis kit (Stratagene, La Jolla, CA) as indicated in
the Materials and methods section. Additionally, we generated
constructs with mutations in the tryptic site located at Gc 761.
Although there are many potential proteolytic sites in the Gc
glycoprotein (Gentsch and Bishop, 1979), the tryptic site at
position 761 is uniquely accessible in the whole virion prior to
acidification, and its accessibility is affected by the confor-
mational changes that are induced by low pH (Gonzalez-
Scarano, 1985). Therefore, it is of interest to determine
whether or not this tryptic site is involved in Gc-mediated
fusion. All of the mutations were engineered into construct
pBluescript II KS(+)-LAC(M), then subcloned into the
expression vector pCAGGS (Niwa et al., 1991) and sequenced
to verify that there were no additional mutations, as previously
described (Plassmeyer et al., 2005).
Expression studies of LACV Gc (1066–1087) mutant constructs
To examine expression as an index of conformational
integrity, the LACV wild-type and amino acid point mutant
constructs were transiently expressed in QT6 cells. Forty-eight
hours after transfection, the cells were stained with conforma-
tional monoclonal antibodies (MABs) 807–31 and 807–22
against LACV Gc (50:50, vol/vol), and expression was
determined by flow cytometry (Fig. 1) (Gonzalez-Scarano et
al., 1982). Expression of LACV (D1078A), LACV (V1076A),
LACV (G1067A), LACV (W1066A), LACV (S1077N), and
LACV (L1074A) was similar to that of the LACV wild-type Gc
(Figs. 1A and B); expression was not detected with mutant
LACV (G1083L) (Fig. 1C). In addition, expression of the two
tryptic site mutant glycoproteins, LACV (R761A), and LACV
(R761H), was also similar to that of wild-type LACV (Fig. 1D).
Two recombinants, LACV Δ1066–1087 (deletion of the entire
putative fusion domain) and LACV SFV FP (insert of the SFV
fusion domain, SVF FP), were also examined, but there was no
expression above background (Figs. 1C and D).
To determine if LACV Δ1066–1087 Gc, LACV SFV FP, and
LACV (G1083L) were expressed at all, Hela cells transfected with
LACVand mutant constructs were examined by IFA at 6, 12, 18,
and 48h after application of DNA using conformation independent
MABs, 807–25 and 807–15 and aMAB-specific for LACVGn, as
well as conformation-dependent MABs 807–22 and 807–31. Gn
and Gc were detected with non-conformational antibodies in Hela
cells transfected with LACV wild-type and mutant constructs
LACV (V1076A, G1067A, W1066A, S1077N, L1074A,
L1074A, D1078A, R761A, R761H, Δ1066–1087, G1083L, and
SFVFP) (Fig. 2). In contrast to the results with non-conformational
antibodies, which detected all of the constructs, three mutants,
LACV Δ1066–1087, LACV (G1083L), and LACV (SFV FP)
were not detected by staining with the conformational antibodies.
Therefore, although deletion of the putative fusion domain or aG to
L substitution at position 1083 did not interfere with expression ofthe glycoprotein, these mutations were not well tolerated as
demonstrated by the their altered conformation.
Mutations within the putative fusion domain, LACV Gc
(1066–1087), reduce or abrogate cell-to-cell fusion
The parental construct and mutants LACV (W1066A),
LACV (G1067A), LACV (V1076A), LACV (L1074A), LACV
(D1078A), LACV (S1077N), LACV (D1078A), LACV
(G1083L), LACV (R761A), LACV (R761H), LACV (Δ
1066–1087), and LACV (SFV FP) were tested in a previously
described fusion assay where QT6 served as the effector cells
and BSR cells functioned as the target cells (Plassmeyer et al.,
2005). In this assay, the pH threshold for cell-to-cell fusion in
cells that expressed the LACV wild-type M segment was just
below 6.2, similar to the pH previously described as critical for
triggering fusion by the native LACV glycoproteins (data not
shown) (Pobjecky et al., 1986). Not surprisingly, the three
constructs that were not detectable by conformational anti-
bodies, LACV (G1083L), LACV (Δ1066–1087), and LACV
(SFV FP) did not mediate cell-to-cell fusion above background
(Figs. 3C and D). However, under these experimental condi-
tions, all of the constructs that demonstrated expression similar
to LACV- mediated cell-to-cell fusion with the exception of
LACV (W1066A) (Figs. 3A and B). The other fusion peptide
mutant constructs, LACV (G1067A), LACV (V1076A) LACV
(L1074A), LACV (S1077N) and LACV (D1078A), demon-
strated decreased fusion efficiency (at least 10-fold lower
signal) in comparison to the wild-type LACV. Additionally,
substitutions G1067A, V1076A, L1074A, and D1078A
appeared to have lower pH thresholds for initiating membrane
fusion (Figs. 3A and B). Point mutations in the tryptic site
located at 761, LACV (R761A) and LACV (R761H), did not
affect the magnitude or pH threshold of cell-to-cell mediated
fusion (Fig. 3E).
The percent maximum fusion for each construct at each pH
was determined for LACV and mutants G1067A, V1076A,
L1074A, and D1078A, then analyzed by nonlinear regression
with a sigmoidal dose-response model (variable slopes) using
GraphPad Prism software, version 4.02 (GraphPad Software,
San Diego, Ca) (Martin-Garcia et al., 2005). The pH50 values (at
which there is 50% fusion signal) were obtained from the
nonlinear regression for each construct and compared by using a
t test. The pH50 values for the four mutant constructs were
significantly (p<0.005) different from wild-type LACV, further
indicating that these amino acid substitutions alter Gc-mediated
fusion (data not shown). Importantly, the effect of these
mutations on fusion was not the result of altered cellular
conformation or reduced expression of the mutant glycoprotein,
as their expression profiles were equivalent to those of the wild-
type construct (Figs. 1 and 2).
Transduction of CHME-5 cells by LACV wild-type and mutant
M segment pseudotyped MLV particles
To assess the effects of themutationswithin this putative fusion
domain on entry, we prepared murine leukemia virus (MLV)
Fig. 1. Surface expression of mutant Gc in QT6 cells measured by flow cytometry. QT6 cells were transfected with M-segment constructs as indicated in the histogram
and fixed with 2% paraformaldehyde for 20min. Gc was detected with a 1:100 dilution of a 1:1 (vol/vol) mixture of two conformational mAbs, 807:31 and 807:22. (A)
As shown in these representative histograms, surface expression of Gc was consistent between the wild-type LACVGc and the mutant LACVGc constructs: W1066A,
G1067A, and V1076A, in panel (B) for constructs L1074A, S1077N and D1078A and in panel (D) for tryptic site mutant constructs R761H and R761A. (C) Surface
expression above background was not detected for G1038L, SFV FP, or (D) LACV (Δ1066–1087) constructs.
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mutant LACVM segment constructs using a previously described
three-plasmid system (Soneoka et al., 1995). Concentrated
pseudotypes were analyzed by Western blot for the presence of
Gc, Gn (Plassmeyer et al., 2005) and MLV Gag p30 to confirm
that pseudoviral particles had been produced (Fig. 4A). The
pseudotypes were then transduced into CHME-5 cells and titrated
using the expression of beta-galactosidase to quantify the
efficiency of entry (Fig. 4B). While pseudotype particles
containing with mutations in the tryptic site at 761, LACV
(R761A and R761H), were able to mediate entry to the same
extent as wild-type LACV Gc (data not shown), pseudotype
viruses with mutations elsewhere in Gc demonstrated eitherFig. 2. Expression of mutant constructs by Immunofluorescence assay (IFA). Gc was
and 807–25 (1:1, vol/vol). Gn was detected by a monoclonal antibody (Jacoby e
(W1066A), and LACV Δ 1066–1087.reduced or abrogated ability to mediate entry. Consistent with the
fusion assays, of the Gc constructs that were detectable by
conformational antibodies, only LACV (G1067A) and LACV
(V1076A)mediated pseudotype virus entry into cells. Pseudotype
virus incorporating mutations G1067A and V1076A transduced
CHME-5 cells significantly less well than wild-type LACV Gc
(p<0.02). As in the fusion assay, mutant W1066Awas unable to
mediate entry in spite of normal expression.
Discussion
We substituted several conserved and non-conserved amino
acid residues within the LACV Gc (1066–1087) to examine thedetected by IFAwith a combination of two non-conformational mAbs: 807–15
t al., 1993). Representative images shown here for pCAGGS, LACV, LACV
Fig. 3. Substitutions within the LACV Gc amino acid region 1066–1087 affect pH-dependent cell-to-cell fusion. Effector cells (QT6) were transfected with two
plasmids: a pCAGGS-M segment construct and a plasmid encoding the Luciferase gene under a T7 promoter. BSR target cells were infected with a vaccinia
virus encoding the T7 RNA polymerase (vTF1.1) as indicated in Materials and methods. Following an overnight incubation, the effector cells were overlaid onto
the target cells, and the pH dropped briefly using HEPES-MES buffers. Luciferase activity, which indicates fusion of cells expressing the T7 polymerase and
cells expressing M-segment constructs, was then measured in the cell lysates obtained 5h later. (A) Amino acid substitutions that either decreased fusion or
abrogated fusion: G1067A, V1076A, and W1066A. (B) Amino acid substitutions decreased fusion: L1074A, D1078A, S1077N (C and D) Amino acid changes
that abolished cell surface expression and also eliminated fusion activity: G1083L, SFV FP, and Δ 1066–1087. (E) Point mutations in the tryptic site located at
761, LACV (R761A) and LACV (R761H) did not affect cell-to-cell fusion.
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Gc (1066–1087) mutants demonstrate that multiple mutations
within the hydrophobic, putative fusion peptide (1066–1087) of
LACV Gc affect expression, shift the pH threshold, and reduce
or abrogate total fusion (Summarized in Table 2). All of the
mutant constructs expressed Gc and Gn, as detected by non-
conformational antibodies. However, we were unable to detect
three of the mutant Gc constructs [LACV Δ1066–1087, LACV
(G1083L), and LACV (SFV FP)] with conformational anti-
bodies. These mutations may have destabilized the hydrophobic
domain resulting in altered conformation of Gc. In contrast,
amino acid substitutions that did not alter expression may have
affected the intra- and intermolecular salt bridges and hydrogen
bonds, ultimately affecting fusion efficiency and pH threshold.
The reduced pH threshold, decreased fusion efficiency and entry
observed for the Gc (1066–1087) point mutant constructs may
represent a difference in the overall ability of mutant Gc (1066–
1087) to undergo a pH-induced conformational change into a
fusion active structure. Alternatively, wild-type and mutant Gc
may undergo a conformational change into a fusion active
structure at a similar efficiency, but the mutations may result in a
Gc glycoprotein that is less fusogenic. The ability to detectLACV (G1067A), (V1076A), (W1066A), (S1077N),
(D1078A), and (L1074A) mutant glycoproteins with conforma-
tional antibodies suggests that these mutations do not adversely
affect the processing, intracellular transport, and overall
conformation of these mutants and support the latter hypothesis.
Importantly, abrogation of cell-to-cell fusion by the amino acid
substitution W1066A, which maintained surface expression,
supports a direct role for LACV Gc (1066–1087) in LACV Gc-
mediated fusion and entry.
Since minor amino acid substitutions within LACV Gc
(1066–1087) have a significant effect on fusion activity, a
specific sequence may be necessary for its full activity. It is
helpful to consider these results in comparison with point
mutation studies of putative fusion domains for several viruses
containing internal fusion peptides such as VSV, ASLV, TBE
and SFV (Allison et al., 2001; Durrer et al., 1995; Hernandez and
White, 1998; Levy-Mintz and Kielian, 1991; Whitt et al., 1990).
Substitutions of amino acids within the fusion peptides of these
viruses have similar phenotypic consequences, including altered
fusion protein expression, reduced/abrogated fusogenicity and,
in some cases, modification of oligomerization and virus
assembly (Allison et al., 2001; Fredericksen and Whitt, 1995,
Table 2
Expression and fusion phenotype for LACV Gc (1066–1087) amino acid
deletion and substitution mutant constructs and LACV Gc 761 tryptic site
mutant constructs
Construct Expression⁎
(Nonconform. Abs)
Expression
(Conform Abs)
Fusion
W1066A Yes Yes −
G1067A Yes Yes ++
L1074A Yes Yes ++
V1076A Yes Yes +
S1077N Yes Yes ++
D1078A Yes Yes +
R761A Yes Yes ++++
R761H Yes Yes ++++
G1083L Yes No −
Δ1066–1087 Yes No −
SFV FP Yes No −
See results for details of determination of expression using microscopy and
FACS.
Fig. 4. MLV pseudotypes of LACVwith mutations in the putative fusion peptide
demonstrate reduced or abrogated ability to transduce CHME cells. (A) Western
blot of MLV pseudotyped particles incorporating LACV wild-type and mutant
GC. Pseudotypes were prepared as described in Materials and methods. After
resolution in an 8–16% tris–glycine polyacrylamide gel, the samples were
transferred to a 0.2-μm pore-size nitrocellulose membrane. Top: Wild-type and
mutant GC (as indicated) were detected with mAb 807:31 at a 1:300 dilution.
Bottom: MLV Gag was detected using a monoclonal goat antibody recognizing
MLV p30. (B) M segment pseudotypes were spinoculated onto CHME-5 cells at
1250×g for 2h at 4°C. Data are presented as the mean plus/minus standard
deviation of multiple experiments and were compared by Student's t test.
Constructs significantly different from LACV (p<0.009) are indicated with an
asterisk (⁎) and constructs significantly (p<0.05) different from control (MLV-
pCAGGS) are indicated with a number sign (#). Pseudotype viruses with
mutations in the putative fusion peptide of Gc (1066–1087) demonstrated either
reduced or abrogated cell entry. Of the fusion peptide mutant constructs, only
LACV (G1067A)- and LACV (V1076A)-mediated pseudotype virus entry into
cells, although their ability to mediate entry was significantly reduced compared
to wild-type LACV (p<0.02).
278 M.L. Plassmeyer et al. / Virology 358 (2007) 273–2821996, 1998; Gomara et al., 2004; Russell et al., 2004; Ma et al.,
1999). Direct interaction between LACV Gc (1066–1087) and
the target membrane during fusion remains to be demonstrated.
However, in conjunction with computational modeling suggest-
ing that LACV Gc (970–1350) shares structural similarity with
class II fusion proteins (Plassmeyer et al., 2005), the results
presented in this study support a role for this hydrophobic region
as the LACV Gc fusion peptide.
Two classes of viral fusion proteins have been established.
Class I fusion proteins are represented by the influenza
hemagglutinin protein and by HIV gp41, but also include fusion
proteins from many unrelated virus families; class II fusion
proteins are represented primarily by members of the Flavivir-idae and the Togaviridae (Jardetzky and Lamb, 2004; Kielian
and Rey, 2006). Both class I and class II fusion proteins
experience a tightly regulated conformational change during
fusion. Class I fusion proteins undergo a drastic refolding
between the pre-fusion and post-fusion conformations, and are
arranged as trimers in both the pre-fusion and post-fusion
complex. In contrast, the class II fusion proteins reorganize
rather than refold (Jardetzky and Lamb, 2004) and form trimers
subsequent to dissociation of the homodimers (flaviviruses) or
heterodimers (alphaviruses) by exposure to low pH in the
endosome following internalization. During this reorganization,
the internal fusion loop is exposed and projected towards the
cellular membrane, creating a rod-like structure analogous to the
class I fusion complex.
While this study supports a role for the hydrophobic region,
Gc (1066–1087) as the fusion peptide, absent three-dimensional
structural analysis we cannot demonstrate whether this putative
fusion domain directly inserts into the endosomal membrane
like the alphavirus E1 or the flavivirus E (Modis et al., 2004). It
is also premature to speculate on the potential Gn-Gc
arrangements that could be analogous to other class II fusion
proteins. Nevertheless, a thorough characterization of the
relative contribution of the amino acid residues within the
fusion domain can help elucidate the mechanisms of confor-
mational change and virus entry for the LACV Gc and other
class II fusion proteins. For example, identification of the
flexible “hinge” region, a site of a number of mutations that
affect the pH dependence of fusion in other class II fusion
proteins may lay the foundation for studies targeting the fusion
domain as a possible antiviral strategy for this medically
important virus (Kielian, 2006; Kielian and Rey, 2006).
In addition to examining the effect of mutations within the
putative fusion domain, we examined the contribution of the
tryptic site at Gc position 761 on LACV-mediated fusion and
entry. While there are many potential proteolytic sites through-
out the Gc glycoprotein (Gentsch and Bishop, 1979), the tryptic
site at position 761 is easily accessible prior to acidification
(Gonzalez-Scarano, 1985). Therefore, it was of particular
interest to determine whether or not this tryptic site is involved
279M.L. Plassmeyer et al. / Virology 358 (2007) 273–282in Gc-mediated fusion, since other fusion proteins depend on
trypsin cleavage for activation. Our results suggest that
mutations in the Gc 761 tryptic site do not affect expression,
cellular localization, pH mediated cell-to-cell fusion, or
pseudotype particle transduction. Therefore, it is unlikely this
site plays a direct role in LACV fusion and entry in mammalian
cells. However, it is still unknown whether the tryptic site at Gc
761, or for that matter the amino acid region 860–1442, or the
LACV Gc putative fusion peptide (1066–1087), are critical for
fusion in the mosquitoes. In this regard, it was previously shown
that theM segment is a major determinant of oral transmission of
LACV by mosquitoes (Beaty et al., 1981; Sundin et al., 1987).
Proteolytic enzymes found in the mosquito midgut, including
the large quantities of trypsin produced upon blood feeding
(Noriega and Wells, 1999), increase virus affinity for mosquito
cells. Therefore, while the LACV Gc761 tryptic site does not
appear to play a role in mammalian cells, it may play a critical
role in mediating fusion and entry in mosquito cells. In addition,
it has also been demonstrated that the proteolytic enzymes of the
mosquito midgut remove Gc while leaving Gn intact (Ludwig et
al., 1989). These data suggest that processing of LACV glyco-
proteins in the mosquito midgut may facilitate attachment of
virus protein and suggests that the role of LACV Gc in fusion
and entry in mosquito cells may be different from that in mam-
malian cells (Beaty et al., 1981; Sundin et al., 1987). It is inte-
resting that mutation of a potential tryptic site (R at 859) affected
fusion, although we do not know if this site is used (cleaved) in
the process of fusion (Plassmeyer et al., 2005). Future studies
will focus on the contributions of LACV Gc (1066–1087) and
the tryptic site at Gc 761 in mediating fusion and entry in the
virus's mosquito vector.Materials and methods
Cell culture
293T (human fetal kidney), QT6 (quail fibroblast), BSR
(baby hamster kidney), and CHME-5 (human fetal microglia)
cells were cultured at 37 °C/5% CO2 in DMEM (Invitrogen,
Carlsbad, CA) supplemented with 10% heat-inactivated fetal
calf serum (FCS) (Atlanta Biologicals, Lawrenceville, GA),
penicillin/streptomycin (P/S) (Invitrogen), and L-glutamine
(Invitrogen).
LACV M segment constructs and site-directed mutagenesis
The LACV M segment ORF was subcloned from
pcDNA3.1 into the expression vector pCAGGS (Niwa et al.,
1991) to employ the CMVenhancer and strong chicken β actin
promoter to express the polyprotein, as previously described
(Plassmeyer et al., 2005). Briefly, the LACV M ORF was
amplified using rTth DNA Polymerase XL (PE Biosystems,
Foster City, CA) with a primer set that introduced restriction
cut sites ClaI and XhoI at the 5′ and 3′ ends, respectively. The
PCR cycle consisted of a 93 °C 2-min denaturing step
followed by 35 cycles of (93 °C 30seconds, 48 °C 1min, 72 °C6min) and an extension of 72 °C 10min. The resulting fragment
was digested with both ClaI and XhoI and inserted into the
linearized pCAGGS expression vector digested with ClaI and
XhoI.
To engineer mutations (point, deletion and insertion of SFV
FP) in the putative fusion domain of LACV Gc and the Gc
(761–772) tryptic site, the LACV M segment was subcloned
into pBluescript II KS+using ClaI and XhoI (Plassmeyer et al.,
2005). The point mutations were engineered into the M segment
using the QuikChange II XL site-directed mutagenesis kit
following manufacturer's instructions (Stratagene, La Jolla,
CA). The forward primers used into engineer the substitutions
are listed:
W1066A (5′-GAGAGGACAAGCTCAGCGGGATGCGAA-
GAGTTTGG);
G1067A (5′-AGGACAAGCTCATGGGCATGCGAAGAGT-
TTGGTTGC);
L1074A (5′-GAGTTTGGTTGCGCGGCTGTAAGTGATG-
GG);
V1076A (5′-GGTTGCCTGGCTGCAAGTGATGGGTG-
TGTATTTGG);
S1077N (5′-GGTTGCCTGGCTGTAAATGATGGGTGTG-
TATTTGGA);
D1078A (5′-TGCCTGGCTGTAAGTGCTGGGTGTGTAT-
TTGGA);
G1083L (5 ′-GATGGGTGTGTATTTCTATCATGCC-
AAGATATA);
R761A (5′-GCCTGCTTATCGCCAGCCTCAGGTGC-
TATATATGC);
R761H (5′-GCCTGCTTATCGCCACACTCAGGTGC-
TATATATGC);
Δ1066–1087 (5′GAGAGGACAAGCTCAGGCGTGTACC-
CGTTCATGTGGGGAGGGGCATATTGCTT-
CTGCGACTCAAGAAAACATAATAAAAGA-
AGAACTATCTGTCTATAGG);
SFV (GAGAGGACAAGCTCAATAATAAAAGAAG-
AACTATCTGTCTATAGG)
For all constructs, the reverse primer is the reverse comple-
ment of the respective sequence. For LACV (Δ1066–1087)
primer: bold sequence is 5′ to the fusion peptide while the
underlined sequence is 3′ to the putative fusion peptide. For
LACV insert SFV primer: underlined sequence is complemen-
tary/identical to LACV sequence flanking the putative fusion
peptide and the bold sequence is the sequence of the SFV fusion
peptide. The point mutant constructs were then cloned into the
expression vector pCAGGS. These M segment clones were
sequenced to verify that there were no additional mutations.
Expression of wild-type and mutant LACV Gc in QT6 cells:
detection by flow cytometry
QT6 cells were plated at a density of 5×105 cells/well in 6-
well plates and cultured overnight. Cells were transfected using
the ProFection Mammalian Transfection System-Calcium
Phosphate (Promega) with 6μg/well of the M segment
280 M.L. Plassmeyer et al. / Virology 358 (2007) 273–282constructs. 48h after application of DNA, the cells were
removed using 0.5mM EDTA and washed twice in PBS before
fixation using 2% paraformaldehyde at 4 °C. LACV Gc was
detected at 4 °C with a 1:100 dilution of either individual
monoclonal antibodies 807–31 and 807–22 (Gonzalez-Scarano
et al., 1982) or a cocktail of the two mAbs, 807–31 and 807–22
(vol/vol) and goat anti-mouse FITC conjugated mAb (Sigma) at
a 1:75 dilution.
Expression of wild-type and mutant GC in QT6 cells: detection
by IFA and confocal microscopy
Individual German glass cover slips (Electron Microscopy
Sciences, Hatfield, PA) plated in 24-well plates were coated
with poly-D-lysine overnight then washed with tissue culture
grade water and dried. QT6 cells (Invitrogen) were plated on
cover slips at a density of 8×104 cells/well and cultured
overnight at 37 °C/5% CO2 in culture media. Cells were
transfected for 6h using the ProFection Mammalian Transfec-
tion System-Calcium Phosphate (Promega, Madison, WI) with
1μg/well of each plasmid (M segment constructs cloned into
pCAGGS). Zero, 6, 12, 18 and 42h after removal of the DNA,
cells were fixed in 2% paraformaldehyde and permeabilized
with 0.5% Triton X-100 at 4 °C. Gn was detected with a 1:100
dilution of a Gn-specific monoclonal antibody. GC was
detected with a 1:100 dilution of a mix of two non-
conformational mAbs, 807:15 and 807:25 (vol/vol), and goat
anti-mouse fluorescein (FITC) conjugated mAb (Sigma, St.
Louis, MO) at a 1:75 dilution. Cells were counterstained with
a 1:500 dilution of Hoechst. Cells were viewed at 40×, and
images were captured using a Leica DC 500 digital camera
(Leica, Northvalle, NJ).
Cell-to-cell fusion assay
Cell-to-cell fusion assays were performed as described
(Plassmeyer et al., 2005). Briefly, effector cells (QT6) were
plated on 6-well plates at 8×105 to 1×106 cells/well and
incubated overnight at 37 °C. Cells were transfected using the
ProFection Mammalian Transfection System-Calcium Phos-
phate (Promega) with 6μg/well of each plasmid, the M segment
construct plus the T7LUC vector. The transfected cells were
maintained at 37 °C for 48h. Target cells, either QT6 or BSR
cells, were plated and incubated overnight at 37 °C in a 24-well
plate at a density of 8×104 cells/well. The target cells were
infected with activated recombinant vaccinia expressing T7
RNA pol (vTF1.1) at a MOI of 2–3 pfu/cell using 0.5–1ml/well
for 1–2h at 37 °C with gentle rocking every 15–20min. vTF1.1
was activated by incubation with trypsin 0.25% [1:1] for 30min.
at 37 °C, then diluted at least 1:10 with Opti-MEM (Invitrogen).
Following infection with vTF1.1, the target cells were washed
with 0. 5ml PBS, cultured in 2ml of DMEM supplemented with
10% FBS and 100μg/ml rifampicin, then incubated overnight at
32 °C. Effector cells were collected with 0.5mM EDTA,
pelleted, washed with PBS, and overlaid onto the target cells for
90min. Cells were exposed to fusion medium (DMEM, 10%
FBS, 1XP/S, 10mM HEPES, and 10mMMES; pH 7.2–5.0) for30s. Following exposure to fusion medium, the cells were
cultured at 37 °C in culture medium containing rifampicin for 5–
8h. Cells were lysed with Promega's reporter lysis buffer and
Luciferase activity was evaluated and measured in a LumiCount
Luminometer (Packard).
Pseudotype production
A previously described transient three-plasmid system was
used to produce Gn/Gc-pseudotyped murine leukemia virus
(MLV) particles (Ma et al., 1999; Soneoka et al., 1995); for
these experiments the glycoproteins were expressed in
pCAGGS, as described above. Supernatants containing pseu-
dotypes were concentrated through 20% sucrose in an SW41
rotor at (150,000×g) at 4 °C for 1h 45min (Burns et al., 1993;
Ma et al., 1999). The pellets were resuspended overnight in
TNE (50mM Tris–HCl, pH 8.0, 130mM NaCl, and 1mM
EDTA).
Western blots for pseudotype particles
Western blot analysis was performed on concentrated
pseudotype particles. For non-reducing conditions, 20μl
pseudotype particles were mixed with 4× loading buffer
(0.2M Tris, 0.4% sodium dodecyl sulfate, 40% [vol/vol]
glycerol, 0.04% [wt/vol] bromophenol blue) and boiled for
4min. Samples were resolved on 8–16% tris–glycine poly-
acrylamide gels (Cambrex, East Rutherford, NJ) then transferred
to 0.2-μm pore-size nitrocellulose membrane (BioRad, Hercu-
les, CA). MLV Gag was detected using monoclonal goat
antibody that recognizes p30. Primary antibody was detected
with a secondary mouse anti-goat horseradish peroxidase (HPR)
conjugated mAb (Sigma). Pseudotype particles containing the
wild-type LACVMand LACVmutant constructs were analyzed
with an anti-Gn and an anti-Gc (807:31) mAb at a 1:500 dilution.
Primary antibody was detected with a sheep anti-mouse HRP
conjugated mAb (Sigma) at 1:10,000, respectively. Detection of
HRP was performed with the SuperSignal West Pico Chemilu-
minescence substrate (Pierce, Rockford, IL) following manufac-
turer's instructions.
Spinoculation and beta-gal detection
Cells were plated in a 96-well plate at a density of 1×104
cells/well and incubated overnight at 37 °C. Serial 10-fold
dilutions of the pseudotyped viruses in culture medium
equilibrated to a final volume of 100μl were then added to
the cells. The cells were centrifugated/spinoculated at 1250×g
for 2h at 4 °C to facilitate transduction. Following the
centrifugation step, the cells were cultured at 37 °C for 48h,
then stained for beta-gal expression as previously described
(Ma et al., 1999).
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